High-power radiofrequency ablation with optimized pulsing algorithm for renal tumors: initial clinical experience and safety profile

Incidental diagnosis of renal cell carcinoma is increasing. While surgery remains the standard treatment for localized T1b or larger lesions, image-guided percutaneous ablation represents a valid alternative for T1a cases. Radiofrequency ablation (RFA) is effective but limited by smaller ablation volumes and sensitivity to the heat-sink effect. Microwave ablation and cryoablation have emerged to address these limitations, although the first is susceptible to thermal injury to adjacent structures and the second requires multiple, larger probes and longer procedures. High-power RFA (HP-RFA) is a recent development that delivers higher energy (370 versus 200 W), enabling faster and larger ablations. This study evaluated the feasibility and safety of a novel HP-RFA system incorporating an impedance-controlled pulsed algorithm and internally cooled electrodes. Five patients with small renal tumors (mean diameter 2.3 cm) unsuitable for surgery underwent ultrasound- or computed tomography-guided HP-RFA. Technical success, safety, and early tumor control were assessed. All procedures were technically successful. No major complications occurred; one minor perirenal hematoma was managed conservatively. Follow-up imaging at 6 months demonstrated complete tumor ablation without local recurrence. These preliminary findings suggest that HP-RFA is feasible and safe for treating small renal tumors and may represent a promising evolution of RFA. Further studies are needed. KEY POINTS: Question Can HP-RFA provide feasible and safe minimally invasive treatment for small renal tumors while overcoming limitations of conventional RFA? Findings Technical success and efficacy of HP-RFA were achieved in 100% of cases. No major complications. Complete tumor ablation was accomplished. Relevance statement HP-RFA demonstrates feasibility, safety, and effective early tumor control in small renal tumors. By enabling larger, faster ablations, it may overcome limitations of conventional RFA and expand the employment of minimally invasive treatment options instead of surgical approaches.

Authors

Institutions

Publication Details

Journal
European Radiology Experimental
Published
2026-11-06
DOI
https://doi.org/10.1186/s41747-026-00833-9
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High-power radiofrequency ablation with optimized pulsing algorithm for renal tumors: initial clinical experience and safety profile

Marco Solbiati, Pierluigi Glielmo, Luca Maria Sconfienza, Eleonora Rossi et al.
European Radiology Experimental
Renal cell carcinoma treatment
article

High-power radiofrequency ablation with optimized pulsing algorithm for renal tumors: initial clinical experience and safety profile

Marco Solbiati, Pierluigi Glielmo, Luca Maria Sconfienza, Eleonora Rossi, Giovanni Mauri, Eric Cosman
article en

Abstract

Incidental diagnosis of renal cell carcinoma is increasing. While surgery remains the standard treatment for localized T1b or larger lesions, image-guided percutaneous ablation represents a valid alternative for T1a cases. Radiofrequency ablation (RFA) is effective but limited by smaller ablation volumes and sensitivity to the heat-sink effect. Microwave ablation and cryoablation have emerged to address these limitations, although the first is susceptible to thermal injury to adjacent structures and the second requires multiple, larger probes and longer procedures. High-power RFA (HP-RFA) is a recent development that delivers higher energy (370 versus 200 W), enabling faster and larger ablations. This study evaluated the feasibility and safety of a novel HP-RFA system incorporating an impedance-controlled pulsed algorithm and internally cooled electrodes. Five patients with small renal tumors (mean diameter 2.3 cm) unsuitable for surgery underwent ultrasound- or computed tomography-guided HP-RFA. Technical success, safety, and early tumor control were assessed. All procedures were technically successful. No major complications occurred; one minor perirenal hematoma was managed conservatively. Follow-up imaging at 6 months demonstrated complete tumor ablation without local recurrence. These preliminary findings suggest that HP-RFA is feasible and safe for treating small renal tumors and may represent a promising evolution of RFA. Further studies are needed. KEY POINTS: Question Can HP-RFA provide feasible and safe minimally invasive treatment for small renal tumors while overcoming limitations of conventional RFA? Findings Technical success and efficacy of HP-RFA were achieved in 100% of cases. No major complications. Complete tumor ablation was accomplished. Relevance statement HP-RFA demonstrates feasibility, safety, and effective early tumor control in small renal tumors. By enabling larger, faster ablations, it may overcome limitations of conventional RFA and expand the employment of minimally invasive treatment options instead of surgical approaches.

European Radiology ExperimentalVol. 10(1)
University of Vermont (US), University of Milan (IT), IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT)
Good health and well-being
Openalex Percentile: Top 16%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon